Bempedoic Acid and Cardiovascular Outcomes in Statin . . . The risk of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (the first key secondary end point) was 15% lower with bempedoic acid than with placebo, and the
Bempedoic Acid Reduces Major Adverse Cardiovascular Events . . . Tip for Patients: For patients who cannot take a statin, bempedoic acid (Nexletol) is an alternative to statin therapy for prevention of cardiovascular disease in high-risk patients without significant liver or kidney disease
Nexletol shows CLEAR benefit in cardiovascular outcome trial New data for Esperion’s cholesterol lowering daily pill Nexletol, used when statins are not working in people at risk of a heart attack, could inject some momentum into the drug’s slow rollout
NEXLIZET® NEXLETOL® CLEAR Outcomes Trial Information The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0 5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis
Statin alternative lowers heart-related deaths - Harvard Health The cholesterol-lowering drug bempedoic acid (Nexletol) can be a good alternative for people who can't take statins A 2023 study found that compared with a placebo, bempedoic acid can lower the risk of heart attacks and related problems
LABEL - accessdata. fda. gov In the cardiovascular outcomes trial, gout was reported in 3 2% of patients treated with NEXLETOL and 2 2% treated with placebo Advise patients to contact their healthcare provider if symptoms of hyperuricemia occur Assess serum uric acid when clinically indicated
In Brief: Cardiovascular Outcomes with Bempedoic Acid (Nexletol) CONCLUSION ― In one large clinical trial in statinintolerant patients who had or were at high-risk for cardiovascular disease, the oral adenosine triphosphate- citrate lyase (ACL) inhibitor bempedoic acid (Nexletol) modestly reduced the risk of a 4-component composite of major adverse cardiovascular events (MACE) compared to placebo
U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . . ANN ARBOR, Mich , March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded
CLEAR Outcomes: Bempedoic Acid Reduces Cardiovascular Events . . . The non-statin lipid-lowering medication bempedoic acid (Nexletol®) has demonstrated a significant reduction in the risk of cardiovascular events in a large outcomes study of statin-intolerant patients treated for primary or secondary cardiovascular prevention